¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º [E7 MsX  
q/NY72tj0  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ u)a'  
*^] ~RhjB  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) [:iv4>ZZ  
qTT,U9]:  
1. ICAM-1 Z<U>A   
24u x  
2. interleukin 12(IL-12) i^)WPP>4Aw  
y7: tr  
3. tumor infiltrating lymphocyte =>|C~@C?  
er2cQS7R  
4. TCR/CD3 complex `S3>3  
1D F/6y  
5. hematopoietin receptor family x({H{'9?  
KVPR}qTP;  
6. individual idiotype(IdI) kkS~4?- *  
.&1C:>  
7. integrin xyA-P& N  
krB'9r<wa`  
8. colony-stimulatory factor (CSF) k`\R+WK$  
^ B/9{0n'  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© x;LzG t:w  
9zBMlc$X  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? t *G /]  
w%y\dIeI'  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ &QNY,Pj  
?4 S+edX  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ(=4W -z7  
"*z_O  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ ,=QM#l]  
A"v{~  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) T?Fcohz(  
4|?{VQ  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ tV;`fV   
&HW1mNF9  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR)  m#vL*]c}  
bzN-*3YE=  
3. immunoglobulin superfamily (IgSF) ^].jH+7i*  
FQz?3w&ia  
4. selectin !y:%0{l  
+|iYg/2  
5. anti-idiotypic antibody (¦ÁId) }n_p$g[Nj/  
hU]HTX'R  
6. major histocompatibility complex(MHC) j@gMb iu  
I04jjr:<  
7. immunotolerance $2^`Uca  
&,\=3 '  
8. biological reponse modifier(BRM) !" #9<~Q,p  
l%ay I  
9. immune reponse gene (Ir gene) kum#^^4G|  
OO dSKf8  
10. reshaped antibody (or reconstituted antibody) 2aw&YZ&Xo  
TGXa,A{  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© X,aYK;q%z  
FWue;pw3  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ D\w h;r  
`@d<n  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? uwf 5!Z:>  
E!BPE>  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ Aa0b6?Jm  
FLg*R/  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? " 96yp4v@  
|7,L`utp  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ ~R$~&x(b  
iv`O /T  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? WW+l'6.  
] Z8Vj7~  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Sxdsv9w  
iGB_{F~t4}  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ Fhv/[j^X  
[7(-T?_  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? 1im^17 X  
l4n)#?Q?  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ |KB0P@=a  
PH"h n]  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: K{n{KB&_&  
x21dku<6K[  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ?? TMSH  
y/e 2l  
ÃâÒßѧ {t};-q!v$j  
GgaTn!mJt  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1n%?@+W  
Oj<S.fi  
1. CD8 aP'"G^F   
ikE<=:pe  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) ~|wbP6</:-  
pJN${  
3. immunoglobulin fold(Ig fold) \om%Q[F7a  
 L4uFNM]  
4. cadherin (Ca-dependent cell adhesion moleculers) ng:Q1Q9N  
kB5.(O  
5. idiotype-anti-idiotypic antibody immune network theory n$xQ[4eH)  
(KvROV);  
6. HLA class II antigen Y.^=]-n,  
?f/n0U4w  
7. complementarity-determining region (CDR) :!zl^J;  
(knp#   
8. perforin(or pore-forming protein ,PFP) `K ,1K  
) }9rwZ  
9. high affinity IL-2 receptor ?W  E  
=)|-?\[w  
10. artificial active immunization 2Pc%fuC  
!nAX$i~  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© v9T_ &  
^k<o T'89  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ:kfp_o+J  
(rg;IXAq%  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 1yqJwy;X  
%c[V  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ ]r_;dYa  
Hr$QLtr  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ h,"4SSL  
} (!EuLL  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ Is+O  
Z(!00^  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? 3MRc 4UlB  
2U-3Q]/I}  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ awz;z?~  
w|Nz_3tI  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ '? jlH0;  
*YlV-C<}W"  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 36am-G  
?mlNL/:  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ Q?X>E3=U  
R i^[i}  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© _2N$LLbg  
<\;#jF%V  
1. immunoglobulin gene rearrangement 8n>9;D5n  
Zv#Ll@v  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) +a*tO@HG  
cH>%r^G\  
3. flow cytometry(FCM) 4rrSb*  
4^URX >nx8  
4. carrier effect y '!m4-  
5L!y-3  
5. positive selection of T lymphocytes in thymus "&3h2(#%  
GI&h`X5,e  
6. mouse TH1(Th1) and TH2(Th2) subsets l'eyq}&  
8-O)Xx}cU  
7. perforin (pore-forming protein ,PFP) Hhh0T>gi  
 s~Te  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) XcjRO#s\  
q|),`.eh\  
9. SH-2(src-homology region 2) K1T4cUo  
^ (FdXGs[  
10. Ab2¦Â (internal image) ?5 {>;#0Z  
&c,kQo+pA  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© &Udb9  
tdu$pC6  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? % oo2/aF  
2=^m9%   
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? J_4!2v!6e  
bR)(H%I  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠsL$:"=  
S@/IQR  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ q0zr E5  
y9Usn8  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠKuu *&u  
&*aIEa^  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) , JQp'e  
73\JwOn~  
ÃâÒßѧרҵ£º Zo~  
71t* %  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ O[ef#R!  
%Da1(bBh  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? I<6P;  
}WH&iES@P  
´«È¾²¡Ñ§×¨Òµ£º :BV6y|J9O^  
_dhgAx-H)h  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ !'9Feoez  
@X;!92i  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ 7Bd-!$j+  
!`Hd-&}bYz  
Ïû»¯×¨Òµ£º "ozr+:#\  
TI,&!E?;  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ GQUe!G9  
2$g6}A`r  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? f\sQO&  
p o2 !  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ a C\MJ 9  
ij(B,Y  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© '6cWS'9"  
B][U4WJ)  
1. Fas(CD95)/FasL K1+)4!}%U  
P"IPcT%Ob%  
2. common chain of cytokine receptor DpvI[r//'*  
c]n1':FT"  
3 . TCR/CD3 complex 2q=AEv/  
~5%W:qwQ  
4. negaive selection of thymocytes *U,@q4  
r")`Ph@yp  
5. artificial active immune 7e|s wJ>4  
:toh0oB[  
6. anti-idiotypic T?tgd J  
/'l{E  
7. IgSF wnEyl[ac  
(a.z9nqGA  
8. Integrin fzb29 -  
hIs4@0  
9. chemokine `>f6) C-  
F;4vPbH+  
10. B7/CD28 K1"*.\?F  
bMg(B-uF7  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© Z'`g J&6n  
Lsq A* *=  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£  *'.|9W  
K6v6yn p/  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ DCIxRPw  
GP!?^r:en  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ rzhWw-GY  
"}u.v?HYz  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ W=^#v  
+Mo9kC  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ DBW[{D E  
@=bLDTx;c)  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ 2,$8icM  
qON|4+~u%  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© R} eN@#"D  
<k eVrCR  
1. B7/CD28 `18qbot  
A-H&  
2. Th1 subset 1n >X[! 8x  
B8.Pn  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© q+H%)kF  
bU>U14ix<  
4. antibody affinity maturation <C1H36p  
oX#Q<2z*  
5. AP-1 @K\~O__  
5L+>ewl  
6. single chain variable fragment£¨ScFv£© 0LPig[  
0t^M3+nc  
7. NK cell receptor %q/62f 7?  
Eza`Z` ^el  
8. Zinkernagel-Doherty phenomenon **w!CaqvY  
@oNH@a j%  
9. Ig fold qW$<U3u}  
:By?O"LQ  
10. CD40/CD40L eV 2W{vuI  
%}SGl${-  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© lW+\j3?Z$  
<Y*+|T+&d  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ mPOGidxix  
:Ux?,  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ J ][T"K  
M`. tf_x  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ HFKf kAl  
q4R5<LW"  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 00G%gQXk,  
na#CpS;pc  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ -l`f)0{  
))R5(R  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ p6 ]7&{>  
kY&k-K\  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ H;?{BV  
y[`l3;u:'  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© gi(H]|=a  
6 )Hwt_b  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© W0y '5`  
%dRo^E1p  
1.Co-stimulators (or co-stimulating molecules) W 0(_ ~  
| h`0u'#  
2.NK-kB L; T8?+x  
|S_T^'<W  
3.Immunoglobulin superfamily qHsUP;7  
?5U2D%t  
4.antigen-presenting cell (APC) )i~cr2Hk  
d_AK `wR  
5.death domain wmk *h-  
8MK>)P o)  
6.CCR and CXCR p`mS[bxv!  
)!Jc3%(B  
7.Lectin (or mitogen) pwO>h>ik  
,/YF-L$(t  
8.Clusters of differentiation, CD) ^g*pGrl#  
w<C#Bka  
9.B7 family ]p*l%(dhY  
AcS|c:3MUy  
10.Cytotoxic T lymphocyte, CTL) 4A@NxihH  
cnSJ{T  
11.IL-15 and IL-15 receptor (IL-15R) D5$wT I  
,%n\=  
12.MHC restriction L>MLi3{  
{xwm^p(f  
13.Affinity-chromatography UV5Ie!\nm  
]NjX?XdX<  
14.Cyctosprin A, CsA x6(~;J  
&?VQ,+[ <  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) Kpb#K[(]&  
#@^t;)|  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© .9R [ *<  
SPN5dE.@  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 el2bd :  
AP [|Ta  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ z."a.>fPaO  
 pF&( 7u  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ !g Z67  
b}0,\B%  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Vm%1> '&  
p+l!6  
ÃâÒßѧרҵ£º 3mYiQ2  
TftHwe):V  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ I([!]z  
/E Bo3 `  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ M(jgd  
Wi[~fI8^!  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ ~2<7ZtV=  
SxdE?uCUS  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) n3}!p'-CC  
KC(xb5x Y  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) /V8}eZ97  
!6s"]WvF  
1. ADCC(antibody dependent cell-mediated cytotoxicity) d@ Y}SWTB  
QA2borfy  
2. »·æß¾úËØ(cyclosporin) {T4  
~vXaqCX  
3. KIR(killer cell inhibitory receptor) p[<Dk$7K  
6:q"l\n>  
4. HLDA(human leucocyte differentiation antigen) 6T +FH;h  
N` aF{3[  
5. Interleukin 18(IL-18) rA2 g&  
2kdC]|H2?  
6. ÕûºÏËØ(integrin) t]$P1*I  
@fs`=lL/  
7. Fas/FasL \"CZI<=TB  
$-#Yl&?z9  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) w;k):; $  
Jd5:{{ Lb  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) OR}c)|1  
F;gx%[$GX  
10. Th1/Th2 vhsk 0$f   
)dY=0"4Z  
11. »ùÒòÒßÃç(DNAÒßÃç) %=?cZfFqO  
PQK(0iCo4  
12. chemokines and chemokine receptor .C2TQ:B,.  
iXj o[Rz^C  
13. ÃâÒßÄÍÊÜ +n<k)E@>J  
AtF3%Z v2  
14. ¹²´Ì¼¤·Ö×Ó {e+- vl  
) RO<o O  
15. ËÀÍö½á¹¹Óò(death domain) YnxRg  
|N}P(GF  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 6 oLwfTy  
6KVn nK  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? YO}1( m  
SB5&A_tr  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ=JKv:</.G  
P>sFV  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î x.3J[=z=>  
 ={5#fgK>  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ~(pmLZ<GW}  
(y?I Tz9  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå ]S(%[|  
H}H7lO  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ [Z~ 2  
a)S+8uU  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) _UT$,0u_i  
B*~5)}1op  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ OM|Fwr$  
TYlbU<  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ ,_X /Gb6)  
zH>hx5,k'X  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛÌ³ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»